Full Press Release Details
fda issues complete response letter crl for aflibercept 8 mg biologics license application solely due to an ongoing review of inspection findings at a third party filler.
REGN
fda issues complete response letter crl for aflibercept 8 mg biologics license application solely due to an ongoing review of inspection findings at a third party filler
Key Takeaway: fda issues complete response letter crl for aflibercept 8 mg biologics license application solely due to an ongoing review of inspection findings at a third party filler